Can nitrofurantoin cause thrombocytopenia (low platelet count)?

Can Nitrofurantoin Cause Low Platelets?

Yes, nitrofurantoin can cause thrombocytopenia (low platelet count), though this is a rare adverse effect. This is explicitly documented in the FDA drug label as a recognized hematologic adverse reaction 1.

Evidence from FDA Drug Label

The official FDA prescribing information for nitrofurantoin lists thrombocytopenia among its laboratory adverse events 1. The drug label specifically states: "The following laboratory adverse events have been reported with the use of nitrofurantoin: increased AST (SGOT), increased ALT (SGPT), decreased hemoglobin, increased serum phosphorus, eosinophilia, glucose-6-phosphate dehydrogenase deficiency anemia, agranulocytosis, leukopenia, granulocytopenia, hemolytic anemia, thrombocytopenia, megaloblastic anemia" 1.

Importantly, the label notes that "in most cases, these hematologic abnormalities resolved following cessation of therapy," though aplastic anemia has been reported rarely 1.

Clinical Case Evidence

Recent case reports support this association:

• A 2023 case report documented a 45-year-old woman who developed immune thrombocytopenia (ITP) with a platelet count of 1 × 10⁹/L three weeks after nitrofurantoin exposure for a UTI 2. She presented with petechiae, fatigue, recurrent epistaxis, and melena, requiring hospitalization with high-dose corticosteroids and IVIG. The authors concluded this was the first reported case linking nitrofurantoin specifically to ITP 2.

• A 2012 case described a patient with systemic lupus erythematosus who developed microangiopathic hemolytic anemia and thrombocytopenia (a TTP-like illness) after nitrofurantoin exposure, responding to plasmapheresis 3.

Mechanism and Context

Drug-induced immune thrombocytopenia occurs through antibody formation—either hapten-dependent antibodies, drug-induced platelet-reactive autoantibodies, or drug-dependent antibodies targeting platelet membrane glycoproteins 4. While nitrofurantoin is not among the most commonly implicated drugs (which include quinine, sulfonamides, NSAIDs, and anticonvulsants) 4, the FDA label and emerging case reports confirm it as a recognized cause.

Clinical Implications

If a patient develops thrombocytopenia while taking nitrofurantoin:

1. Immediately discontinue the drug 1, 2
2. Check a complete blood count to confirm isolated thrombocytopenia and rule out pseudothrombocytopenia
3. Assess bleeding risk based on platelet count and clinical symptoms
4. For severe thrombocytopenia (<10 × 10⁹/L) with bleeding, consider hospitalization with platelet transfusions, corticosteroids, and/or IVIG 2
5. Monitor platelet recovery after drug discontinuation—most hematologic abnormalities resolve with cessation 1

Common Pitfall

Do not assume thrombocytopenia in a patient on nitrofurantoin is always idiopathic ITP. A careful medication history is essential, as drug-induced thrombocytopenia is a diagnosis of exclusion that requires temporal association with drug exposure 2, 4. The thrombocytopenia typically develops within days to weeks of starting the medication.